TY - T1的规范数据为多个呼吸冲刷的结果在学龄白人孩子摩根富林明——欧洲呼吸杂志乔-和J欧元做10.1183/13993003.01302 -2019 SP - 1901302 AU Anagnostopoulou Pinelopi盟——Latzin菲利普AU -詹森,蕾妮AU -斯特尔,Mirjam AU -哈珀,阿拉娜AU - Yammine,苏菲盟——UsemannJakob AU - Foong, Rachel e AU - Spycher, Ben AU - Hall, Graham L. AU - Singer, Florian AU - Stanojevic, Sanja AU - Mall, Marcus AU - Ratjen, Felix AU - Ramsey，氮气多重呼吸冲洗(氮气多重呼吸冲洗，N2MBW)技术越来越多地被用于评估学龄儿童肺部疾病的通气不均匀程度。然而，目前还没有健康儿童的参考值。本研究的目的是在健康的高加索学龄儿童队列中产生N2MBW结果的参考值。方法收集6 ~ 18岁健康高加索学龄儿童的N2MBW数据。使用超声波流量计(Exhalyzer D, Eco Medics AG, Duernten，瑞士)进行测量，并使用商业软件(Spiroware, 3.2.1, Eco Medics AG)进行分析。生成肺清除率指数2.5% (LCI2.5%)和5% (LCI5%)、矩比(M1/M0和M2/M0)的标准值和正常上限，生成功能剩余容量(FRC)的预测方程。结果对180名6 ~ 18岁健康白种人儿童的485项试验进行分析。虽然LCI随着年龄的增长而增加，但这种增加可以忽略不计(LCI为2.5%，为0.04单位/年)，因此该年龄组确定了正常的固定上限。LCI2.5%的限值为7.91,LCI5%的限值为5.73,M1/M0的限值为1.75,M2/M0的限值为6.15。 Height and weight were found to be independent predictors of FRC.Conclusion We report reference values for N2MBW outcomes measured on a commercially available ultrasonic flowmeter device (Exhalyzer D, Eco Medics AG, Duernten, Switzerland) in healthy school-aged children to allow accurate interpretation of ventilation distribution outcomes and FRC in children with lung disease.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Anagnostopoulou has nothing to disclose.Conflict of interest: Dr. Latzin reports personal fees from Gilead, personal fees from Novartis, personal fees from Polyphor, personal fees from Santhera, personal fees from Schwabe, personal fees from Vertex, personal fees from Vifor, personal fees from Zambon, grants from Vertex, outside the submitted work.Conflict of interest: R. Jensen has nothing to disclose.Conflict of interest: Dr. Stahl reports personal fees from Vertex Pharmaceuticals, outside the submitted work.Conflict of interest: Dr. Harper has nothing to disclose.Conflict of interest: Dr. Yammine has nothing to disclose.Conflict of interest: Dr. Usemann has nothing to disclose.Conflict of interest: Dr. Foong has nothing to disclose.Conflict of interest: Dr. Spycher has nothing to disclose.Conflict of interest: Dr. Hall reports grants from NHMRC, Australia and USA CF Foundation, and non-financial support from ndd, during the conduct of the study.Conflict of interest: Dr. Singer reports personal fees from Vertex, personal fees from Novartis, outside the submitted work.Conflict of interest: Dr. Stanojevic has nothing to disclose.Conflict of interest: Dr. Mall reports grants from German Federal Ministry of Education and Research , grants from Einstein Foundation Berlin, during the conduct of the study; personal fees from Boehringer Ingelheim, personal fees from Vertex Pharmaceuticals, outside the submitted work.Conflict of interest: Dr. Ratjen reports grants and personal fees from Vertex, personal fees from Novartis, personal fees from Bayer, personal fees from Roche, personal fees from Genetech, outside the submitted work.Conflict of interest: Dr. Ramsey has nothing to disclose. ER -